M

yoKardia (MYOK) announced Monday that its experimental drug mavacamten demonstrated statistically significant improvements in blood flow and aerobic capacity in patients with an inherited form of heart disease in a small, mid-stage clinical trial.

Eight of the 10 patients who completed the study achieved improvement in blood flow to a level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Pts with HCM that had operation for it got rid of obstruction but continue to have VO2 problem. Who can I talk to about likely taking them as stage 2-3?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy